In Their Own Words -- Grassley
Posted 08/18/17
-- The settlement “shortchanges the taxpayers…The government's own watchdog said the taxpayers may have overpaid for EpiPen by as much as $1.27 billion over 10 years.”
Senator Charles Grassley, R-Iowa, commenting on the finalized $465 million settlement against Mylan Inc. and Mylan Specialty L.P related to the anti-allergy device EpiPen.